Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Phase 2 Completed 22 enrolled University of Alabama at Birmingham Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

To determine the hearing response rate at 24 weeks after treatment with bevacizumab for symptomatic vestibular schwannomas (VS) in children and young adults with Neurofibromatosis Type 2 (NF 2).

Timeline

Start: 2013-05-15
Primary completion: 2019-01-01
Completion: 2020-02-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Summary

Timeline

Drugs

Indications